Press Releases
Stay up to date with press releases covering announcements, company news, product launches, and business updates.
Publish your press release
VELA Chairs, Parent Company of Enable Me, Named Denmark’s Best Workplace for Second Consecutive Year
EIN Presswire
A 98% employee approval rating and 2026 Great Place to Work® win confirms VELA Chairs’ status as a global leader in quality and workplace excellence.
Allarity Therapeutics CEO to Present at Precision Medicine Forum Europe 2026 in Stockholm
GlobeNewswire, Inc.
TARPON SPRINGS, Fla., May 8, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway...
Zealand Pharma Announces Financial Results for the First Three Months of 2026
GlobeNewswire, Inc.
Company announcement – No. 14 / 2026 Zealand Pharma Announces Financial Results for the First Three Months of 2026 A defining start to 2026, marked by pivotal progress for leading obesity assets, petrelintide and survodutide, and strong momentum...
Lexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical Updates
GlobeNewswire, Inc.
SONATA-HCM anticipated to be fully enrolled mid-2026 Resubmission of NDA for ZYNQUISTA® in type 1 diabetes anticipated mid-2026 with potential for approval this year Clinical development of LX9851 initiated by Novo Nordisk Capital raise,...
Gaza: Red Cross Field Hospital in Rafah undergoes overhaul to continue addressing urgent health care needs
International Committee of the Red Cross
“The entry of medical equipment and supplies for the Red Cross Field Hospital is a positive step towards responding to the medical needs of people in Gaza,” said Julien Lerisson, the ICRC’s head of delegation in Israel and the Occupied...
Zealand Pharma initiates USD 200 million / DKK 1.3 billion share buy-back program
GlobeNewswire, Inc.
Company announcement No. 13 / 2026 Zealand Pharma initiates USD 200 million / DKK 1.3 billion share buy-back program Robust cash position of USD 2.3 billion (DKK 14.5 billion) as of March 31, 2026 Financial strength to be further enhanced by...
Shamrock Medicine Expands Family Medicine Services in Philadelphia and Chestnut Hill with Dr. Monalisa Ghose
EIN Presswire
Board-certified family medicine physician Dr. Monalisa Ghose supports Shamrock Medicine’s primary care access for adults in Philadelphia and Chestnut Hill. PHILADELPHIA, PA, UNITED STATES, May 6, 2026 /EINPresswire.com/ -- Shamrock Medicine, an...
Zealand Pharma - Execution framework for share buy-back program
GlobeNewswire, Inc.
Company announcement No. 15 / 2026 Zealand Pharma - Execution framework for share buy-back program Copenhagen, Denmark, May 7, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company...
Two years on: upgrading the Red Cross Field Hospital in Rafah
International Committee of the Red Cross
Over the last two years, the Red Cross Field Hospital has been a constant in Gaza's fractured health landscape.
Ascendis Pharma Reports First Quarter 2026 Financial Results
GlobeNewswire, Inc.
- Q1 2026 revenue of €197 million for YORVIPATH® and €44 million for SKYTROFA® - More than 1,000 new patient enrollments for YORVIPATH in the U.S. in Q1 - As of May 1, more than 60 YUVIWEL® enrollments since early April U.S. commercial launch -...
U.S., Norwegian, and Danish Chaplains Partner at LRMC to Strengthen Spiritual Readiness
DVIDS - Georgia
LANDSTUHL, Germany – Landstuhl Regional Medical Center (LRMC) recently welcomed a cohort of military chaplains from Norway and Denmark for its Clinical Pastoral Education (CPE) program, held April 20 to May 7. The three-week program is designed to...
Synklino announces first patient dosed in Phase 1 trial of SYN002 for CMV prevention in kidney transplantation
GlobeNewswire, Inc.
Study to evaluate the safety and exploratory efficacy of SYN002 in recipients of human cytomegalovirus (CMV) positive donor kidneys, and to monitor for viral reactivation over the six months following transplantation Investigator-sponsored Phase 1...
Protection of health care in armed conflict: UN Security Council Resolution 2286 10 years on
International Committee of the Red Cross
Thank you, Madam Chair.
New REDUCE-IT® Analysis Presented at the European Atherosclerosis Society (EAS) Congress 2026 Suggests Risk-Weighted ApoB May Improve Identification of Residual Cardiovascular Risk in Statin-Treated Patients with Hypertriglyceridemia
GlobeNewswire, Inc.
DUBLIN and BRIDGEWATER, N.J., May 27, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) (Amarin), a company committed to advancing the science of cardiovascular disease (CVD) worldwide, today announced new data from a post hoc...
The Zealand Pharma Board of Directors proposes to elect Camilla Sylvest to the Board of Directors at an upcoming Extraordinary General Meeting
GlobeNewswire, Inc.
Press release - No. 9 / 2026 The Zealand Pharma Board of Directors proposes to elect Camilla Sylvest to the Board of Directors at an upcoming Extraordinary General Meeting Camilla Sylvest will bring deep commercial expertise to the Board at a...
Zealand Pharma convenes Extraordinary General Meeting on May 26, 2026
GlobeNewswire, Inc.
Company announcement – No. 12 / 2026 Zealand Pharma convenes Extraordinary General Meeting on May 26, 2026 Copenhagen, Denmark, May 1, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology...
Bedrocan and Becanex Launch Strategic Product Cooperation — Joint Market Presence in Germany
EIN Presswire
BERLIN, BERLIN, GERMANY, May 27, 2026 /EINPresswire.com/ -- Dutch medicinal cannabis pioneer Bedrocan and Berlin-based extraction specialist Becanex® are launching a strategic product cooperation.
Zealand Pharma conference call on May 7 at 2pm CET (8am ET) to present first quarter 2026 financial results
GlobeNewswire, Inc.
Press Release – No. 8 / 2026 Zealand Pharma conference call on May 7 at 2pm CET (8am ET) to present first quarter 2026 financial results Copenhagen, Denmark and Boston, Massachusetts, April 30, 2026 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no....
Zealand Pharma and Roche to advance petrelintide, an amylin analog, to Phase 3 trials for chronic weight management
GlobeNewswire, Inc.
Company announcement – No. 11 / 2026 Zealand Pharma and Roche to advance petrelintide, an amylin analog, to Phase 3 trials for chronic weight management Phase 3 trials for chronic weight management planned for initiation in the second half of 2026...
Zealand Pharma announces Boehringer Ingelheim's novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic improvement in people with obesity or overweight in Phase 3 trial
GlobeNewswire, Inc.
Company announcement – No. 10 / 2026 Zealand Pharma announces Boehringer Ingelheim's novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic improvement in people living with obesity...
Sign up for:
Healthcare Times Denmark
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.